148 related articles for article (PubMed ID: 34673692)
1. New Drug for Mismatch Repair Deficient Endometrial Cancer and Solid Tumors.
Aschenbrenner DS
Am J Nurs; 2021 Nov; 121(11):23. PubMed ID: 34673692
[TBL] [Abstract][Full Text] [Related]
2. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
Kasherman L; Ahrari S; Lheureux S
Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
[TBL] [Abstract][Full Text] [Related]
3. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
JAMA Oncol; 2020 Nov; 6(11):1766-1772. PubMed ID: 33001143
[TBL] [Abstract][Full Text] [Related]
4. Dostarlimab: First Approval.
Markham A
Drugs; 2021 Jul; 81(10):1213-1219. PubMed ID: 34106455
[TBL] [Abstract][Full Text] [Related]
5. Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline
Dizon DS; Dias-Santagata D; Bregar A; Sullivan L; Filipi J; DiTavi E; Miller L; Ellisen L; Birrer M; DelCarmen M
Oncologist; 2018 Jun; 23(6):650-653. PubMed ID: 29472312
[TBL] [Abstract][Full Text] [Related]
6. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
[TBL] [Abstract][Full Text] [Related]
7. [New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer].
Galienne M; Rodrigues M
Bull Cancer; 2021; 108(7-8):675-676. PubMed ID: 33994164
[No Abstract] [Full Text] [Related]
8. Dostarlimab: A Review.
Costa B; Vale N
Biomolecules; 2022 Jul; 12(8):. PubMed ID: 35892341
[TBL] [Abstract][Full Text] [Related]
9. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
[TBL] [Abstract][Full Text] [Related]
10. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
Future Oncol; 2021 Oct; 17(29):3781-3785. PubMed ID: 34427115
[TBL] [Abstract][Full Text] [Related]
11. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F
Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982
[TBL] [Abstract][Full Text] [Related]
12. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
Rodrigues M; Eberst L; Follana P; Gauthier L; Jacquemin V; Tessier C; El Mouaddin N; Boudier P; Fiteni F; Angeli E; Roche S; Delanoy N; Sabatier R; Flippot R; de la Motte Rouge T
Bull Cancer; 2023 Oct; 110(10):1041-1050. PubMed ID: 37659907
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.
Arora S; Balasubramaniam S; Zhang W; Zhang L; Sridhara R; Spillman D; Mathai JP; Scott B; Golding SJ; Coory M; Pazdur R; Beaver JA
Clin Cancer Res; 2020 Oct; 26(19):5062-5067. PubMed ID: 32295834
[TBL] [Abstract][Full Text] [Related]
14. New Approved Use for Keytruda.
Aschenbrenner DS
Am J Nurs; 2022 Jul; 122(7):26-27. PubMed ID: 35736598
[TBL] [Abstract][Full Text] [Related]
15. Dostarlimab for the treatment of advanced endometrial cancer.
Redondo A; Gallego A; Mendiola M
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):1-9. PubMed ID: 35184615
[TBL] [Abstract][Full Text] [Related]
16. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
Prasad V; Kaestner V; Mailankody S
JAMA Oncol; 2018 Feb; 4(2):157-158. PubMed ID: 29285544
[No Abstract] [Full Text] [Related]
17. Blocking PD-1 in Tumors with Faulty DNA Repair.
Cancer Discov; 2016 Aug; 6(8):OF6. PubMed ID: 27354272
[TBL] [Abstract][Full Text] [Related]
18. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
[TBL] [Abstract][Full Text] [Related]
20. New Drug Update: Dostarlimab, Loncastuximab Tesirine, and Aducanumab.
Gettman L
Sr Care Pharm; 2022 Jan; 37(1):9-16. PubMed ID: 34953508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]